For the advanced/metastatic disease framework, a treatment or regimen can earn “bonus” points if it can be demonstrated to provide a statistically significant improvement in either palliation of symptoms and/or treatment-free intervals, compared with the control treatment in a prospective clinical trial.
Scores and cost
The Net Health Benefit score will be derived from the combination of the clinical benefit and toxicity score, plus points for regimens designed to treat advanced cancer. The maximum achievable scores are 100 for adjuvant therapies and 130 for advanced/metastatic therapies.
Cost estimates included in the valuation process will include both drug acquisition costs and costs to patients.
ASCO is inviting comments via an online survey through August 21, 2015.